CJC-1295 (no DAC)

Modified GRF 1-29 (CJC-1295 without DAC) is the same 29-amino-acid GHRH sequence as sermorelin but with four key amino acid substitutions (positions 2, 8, 15, and 27) that dramatically improve its resistance to enzymatic degradation by DPP-IV, NEP, and other proteases. These substitutions extend its half-life from ~10 minutes (sermorelin) to ~30 minutes — the ideal window for triggering a single, sharp GH pulse.

The critical distinction from CJC-1295 with DAC is the absence of the Drug Affinity Complex — the reactive NHS-ester that covalently bonds the peptide to serum albumin. Without DAC, the peptide clears within 30–60 minutes and cannot cause the sustained, blunted GH elevation associated with DAC. This makes it the preferred choice for users who want to preserve the natural pulsatile pattern of GH secretion.

CJC-1295 (no DAC) is almost always combined with a GHRP (ipamorelin being the gold standard partner) for synergistic GH release — CJC-1295 amplifies the height of the GH pulse while the GHRP triggers the release mechanism.

// GHRH RECEPTOR AGONISM (SHORT-ACTING)

Like sermorelin, Mod GRF 1-29 binds GHRHR on pituitary somatotrophs and triggers cAMP-mediated GH synthesis and release. The four amino acid substitutions prevent rapid cleavage by DPP-IV at position 2 and NEP at positions 8 and 15, extending bioavailability long enough to fully engage the GH pulse mechanism.

// SYNERGY WITH GHRPs

GHRH and ghrelin/GHRP signalling pathways converge on somatotrophs via independent receptors (GHRHR and GHS-R1a respectively). Co-administration produces multiplicative rather than additive GH release — a 10× amplification compared to either agent alone in some studies. Ipamorelin is the preferred GHRP partner due to its selectivity and lack of cortisol/prolactin stimulation.

// PULSATILE RELEASE PRESERVATION

The 30-minute half-life ensures the peptide clears between doses, allowing somatostatin tone to recover. This preserves the pulse-trough pattern essential for long-term pituitary sensitivity. Continuous GHRH stimulation (as with the DAC version) eventually blunts somatotroph responsiveness — the no-DAC version avoids this.

CJC-1295 (no DAC) is the most widely used GHRH analogue in research and off-label protocols. The standard stack of CJC-1295 (no DAC) + ipamorelin 2–3× daily produces the best-studied GH pulse amplification of any peptide combination, with a favourable safety profile and no significant effect on cortisol or prolactin.

Comparison with CJC-1295 w/DAC: The no-DAC version produces sharper, more physiological GH pulses; the DAC version provides convenience (once-weekly dosing) at the cost of continuous IGF-1 elevation and attenuated pulse amplitude. Most practitioners prefer no-DAC for body composition and recovery protocols where pulse fidelity matters.